Superworth

Indivior Pharmaceuticals free cash flow INDV

Cash from operations less capital spending, by quarter and over the last twelve months, from 2024.

Last 12 months, to Jun 30, 2026
−$111M
Latest quarter, Q2 FY26
$222M
+57% on a year earlier
Fiscal year 2025
−$93M
−1429% on the year before

Indivior Pharmaceuticals' free cash flow was −$111M over the twelve months to Jun 30, 2026, down 164% on a year earlier.

In its latest quarter, Q2 FY26, it was $222M, up 57% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$93M−1429%
FY2024$7Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26$222M+57%−$111M
Q1 FY26−$29M−141%−$192M
Q4 FY25−$245Mn/a−$93M
Q3 FY25−$59Mn/a$119M
Q2 FY25$141M+68%$173M
Q1 FY25$70Mn/a$116M
Q4 FY24−$33Mn/a$7M
Q3 FY24−$5Mn/an/a
Q2 FY24$84Mn/an/a
Q1 FY24−$39Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Indivior Pharmaceuticals' size, closest first, today.

CompanyFree cash flow yield
INDVIndivior Pharmaceuticals−2.7%
ARQTArcutis Biotherapeutics1.0%
LQDALiquidia3.9%
OGNOrganon15.7%
NRIXNurix Therapeutics13.4%
KNSAKiniksa Pharmaceuticals International3.1%
LGNDLigand Pharmaceuticals2.2%
AMRXAmneal Pharmaceuticals2.0%
PBHPrestige Consumer Healthcare10.4%
ALKSAlkermes plc.3.0%
HRMYHarmony Biosciencesn/m
Peer median3.1%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Indivior Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.